{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:20:45Z","timestamp":1791991245631,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017521","name":"Esteve Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105878","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T03:49:14Z","timestamp":1763092154000},"page":"105878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-0798","authenticated-orcid":false,"given":"F.","family":"Spada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7979-4795","authenticated-orcid":false,"given":"F.","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rinzivillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9478","authenticated-orcid":false,"given":"M.","family":"Cinquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.A.","family":"Fittipaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-1806","authenticated-orcid":false,"given":"A.","family":"Tralongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Moschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Albertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-5351","authenticated-orcid":false,"given":"V.","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-5703","authenticated-orcid":false,"given":"V.","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bajetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-4804","authenticated-orcid":false,"given":"S.","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3608-1995","authenticated-orcid":false,"given":"E.","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Buzzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cingarlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Coppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cremonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.G.","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0930-4337","authenticated-orcid":false,"given":"R.","family":"De Robertis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-5482","authenticated-orcid":false,"given":"M.","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-9514","authenticated-orcid":false,"given":"P.","family":"Ferolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4644-1074","authenticated-orcid":false,"given":"L.","family":"Funicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Grana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-4167","authenticated-orcid":false,"given":"T.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-8657","authenticated-orcid":false,"given":"A.","family":"La Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marconcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-8192","authenticated-orcid":false,"given":"S.","family":"Massironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-7684","authenticated-orcid":false,"given":"E.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-5803","authenticated-orcid":false,"given":"R.","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ortolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-1700","authenticated-orcid":false,"given":"M.G.","family":"Papotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6170","authenticated-orcid":false,"given":"S.","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pelosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ramundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-7295","authenticated-orcid":false,"given":"D.","family":"Ravizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Razzore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-2094","authenticated-orcid":false,"given":"G.","family":"Reimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-4404","authenticated-orcid":false,"given":"G.","family":"Rindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.M.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-4372","authenticated-orcid":false,"given":"R.E.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3019-354X","authenticated-orcid":false,"given":"S.","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.M.","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Versari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vigorito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-7796","authenticated-orcid":false,"given":"M.C.","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"M.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-0526","authenticated-orcid":false,"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-4289","authenticated-orcid":false,"given":"F.","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0704","authenticated-orcid":false,"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.esmoop.2025.105878_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib2","first-page":"29","article-title":"Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment","volume":"26","author":"D\u00edez","year":"2013","journal-title":"Ann Gastroenterol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105878_bib3","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.3390\/jcm11133794","article-title":"The increasing incidence of neuroendocrine neoplasms worldwide: current knowledge and open issues","volume":"11","author":"Rossi","year":"2022","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105878_bib4","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","article-title":"Carcinoid and neuroendocrine tumors: building on success","volume":"33","author":"Kunz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105878_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2025.105878_bib6","article-title":"The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines","volume":"352","author":"Brouwers","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.esmoop.2025.105878_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.humpath.2019.12.002","article-title":"Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?","volume":"96","author":"Bellizzi","year":"2020","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105878_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/modpathol.2013.40","article-title":"ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin","volume":"26","author":"Agaimy","year":"2013","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105878_bib10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/clinchem\/46.10.1588","article-title":"Discriminating capacity of indole markers in the diagnosis of carcinoid tumors","volume":"46","author":"Meijer","year":"2000","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000472254","article-title":"ENETS Consensus Guidelines for standard of care in neuroendocrine tumours: biochemical markers","volume":"105","author":"Oberg","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105878_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.md.0000236956.74128.76","article-title":"Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature","volume":"85","author":"Berna","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105878_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MD.0b013e31802b518c","volume":"85","author":"Berna","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jc.2008-1410","article-title":"Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline","volume":"94","author":"Cryer","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105878_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/edrv-12-2-181","article-title":"Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker","volume":"12","author":"Deftos","year":"1991","journal-title":"Endocr Rev"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105878_bib17","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","article-title":"Chromogranin A: is it a useful marker of neuroendocrine tumors?","volume":"25","author":"Campana","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000179900","article-title":"Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors","volume":"89","author":"Welin","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105878_bib19","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1530\/ERC-10-0280","article-title":"Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours","volume":"18","author":"Oberg","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1148\/radiol.12112512","article-title":"Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management","volume":"266","author":"Sahani","year":"2013","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5306\/wjco.v2.i1.28","article-title":"Imaging of gastroenteropancreatic neuroendocrine tumors","volume":"2","author":"Tan","year":"2011","journal-title":"World J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2214\/AJR.09.2760","article-title":"Value of CT enteroclysis in suspected small-bowel carcinoid tumors","volume":"194","author":"Kamaoui","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105878_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000225946","article-title":"ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with 111In-pentetreotide","volume":"90","author":"Kwekkeboom","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105878_bib24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105878_bib25","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105878_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1530\/EC-16-0043","article-title":"A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management","volume":"5","author":"Oberg","year":"2016","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"28","key":"10.1016\/j.esmoop.2025.105878_bib29","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105878_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"10022","key":"10.1016\/j.esmoop.2025.105878_bib32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"9808","key":"10.1016\/j.esmoop.2025.105878_bib33","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105878_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000491999","article-title":"Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours","volume":"107","author":"Raymond","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105878_bib36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hoc.2015.09.009","article-title":"Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors","volume":"30","author":"Kwekkeboom","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105878_bib38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00259-017-3652-1","article-title":"Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105878_bib39","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177LuDOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105878_bib40","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2967\/jnumed.117.202903","article-title":"90Y-DOTATOC dosimetry-based personalized peptide receptor radionuclide therapy","volume":"59","author":"Menda","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib41","first-page":"130","article-title":"Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors","volume":"22","author":"Hindorf","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40618-024-02448-6","volume":"48","author":"Panzuto","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105878_bib44","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105878_bib45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105878_bib46","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors","volume":"92","author":"Fj\u00e4llskog","year":"2001","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105878_bib47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105878_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102899","article-title":"The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms - a systematic review","volume":"134","author":"Arrivi","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105878_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105878_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105878_bib51","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105878_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10446","key":"10.1016\/j.esmoop.2025.105878_bib54","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105878_bib55","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105878_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.08.006","article-title":"Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications","volume":"50","author":"Fazio","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105878_bib58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000445165","article-title":"The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories","volume":"104","author":"Milione","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105878_bib60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105878_bib61","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105878_bib63","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2025.105878_bib64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105878_bib66","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.suronc.2012.05.001","article-title":"Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review","volume":"21","author":"Saxena","year":"2012","journal-title":"Surg Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105878_bib67","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105878_bib68","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105878_bib69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","article-title":"Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis","volume":"230","author":"Egger","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105878_bib70","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","article-title":"Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model","volume":"27","author":"Do Minh","year":"2017","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105878_bib71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13063-018-2782-5","article-title":"Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial","volume":"19","author":"Chen","year":"2018","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105878_bib72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jmri.24363","article-title":"Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET\/CT compared in patients with liver metastases from neuroendocrine neoplasms","volume":"40","author":"Armbruster","year":"2014","journal-title":"J Magn Reson Imaging"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105878_bib73","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1007\/s00330-020-06930-6","article-title":"The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor","volume":"30","author":"Hayoz","year":"2020","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105878_bib74","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/RCT.0000000000000425","volume":"40","author":"Luersen","year":"2016","journal-title":"J Comput Assist Tomogr"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105878_bib75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11154-017-9439-7","article-title":"The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: pros and cons","volume":"18","author":"Sposito","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105878_bib76","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archsurg.2011.186","article-title":"Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database","volume":"146","author":"Gedaly","year":"2011","journal-title":"Arch Surg"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105878_bib77","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplant"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:08:13Z","timestamp":1764302893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017478"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105878","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105878"}}